368 related articles for article (PubMed ID: 32796758)
21. Management of immune checkpoint inhibitor-related dermatologic adverse events.
Si X; He C; Zhang L; Liu X; Li Y; Wang H; Guo X; Zhou J; Duan L; Wang M; Zhang L
Thorac Cancer; 2020 Feb; 11(2):488-492. PubMed ID: 31814310
[TBL] [Abstract][Full Text] [Related]
22. Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitor Therapy.
Ho AK; Ho AM; Cooksley T; Nguyen G; Erb J; Mizubuti GB
Anesth Analg; 2021 Feb; 132(2):374-383. PubMed ID: 33009134
[TBL] [Abstract][Full Text] [Related]
23. Management of immune checkpoint inhibitor-related rheumatic adverse events.
Zhou J; Wang H; Guo X; Wang Q; Duan L; Si X; Zhang L; Liu X; Li Y; Zhang W; Zhang L
Thorac Cancer; 2020 Jan; 11(1):198-202. PubMed ID: 31762209
[TBL] [Abstract][Full Text] [Related]
24. Neurotoxicities associated with immune checkpoint inhibitor therapy.
Duong SL; Barbiero FJ; Nowak RJ; Baehring JM
J Neurooncol; 2021 Apr; 152(2):265-277. PubMed ID: 33454891
[TBL] [Abstract][Full Text] [Related]
25. Neurological Immunotoxicity from Cancer Treatment.
Wesley SF; Haggiagi A; Thakur KT; De Jager PL
Int J Mol Sci; 2021 Jun; 22(13):. PubMed ID: 34201529
[TBL] [Abstract][Full Text] [Related]
26. Clinical diagnosis and treatment recommendations for immune checkpoint inhibitor-related hematological adverse events.
Zhuang J; Du J; Guo X; Zhou J; Duan L; Qiu W; Si X; Zhang L; Li Y; Liu X; Wang H; Zhou D; Zhang L
Thorac Cancer; 2020 Mar; 11(3):799-804. PubMed ID: 32017466
[TBL] [Abstract][Full Text] [Related]
27. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
[TBL] [Abstract][Full Text] [Related]
28. Understanding adverse events of immunotherapy: A mechanistic perspective.
Burke KP; Grebinoski S; Sharpe AH; Vignali DAA
J Exp Med; 2021 Jan; 218(1):. PubMed ID: 33601411
[TBL] [Abstract][Full Text] [Related]
29. Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors.
Xiao Y; Zeng L; Shen Q; Zhou Z; Mao Z; Wang Q; Zhang X; Li Y; Yao W
J Immunol Res; 2020; 2020():2640273. PubMed ID: 32832568
[TBL] [Abstract][Full Text] [Related]
30. Infectious Complications of Immune Checkpoint Inhibitors.
Abers MS; Lionakis MS
Infect Dis Clin North Am; 2020 Jun; 34(2):235-243. PubMed ID: 32334989
[TBL] [Abstract][Full Text] [Related]
31. Characterization and management of neurological adverse events during immune-checkpoint inhibitors treatment: an Italian multicentric experience.
Diamanti L; Picca A; Bini P; Gastaldi M; Alfonsi E; Pichiecchio A; Rota E; Rudà R; Bruno F; Villani V; Galiè E; Vogrig A; Valente M; Zoccarato M; Poretto V; Giometto B; Cimminiello C; Del Vecchio M; Marchioni E
Neurol Sci; 2022 Mar; 43(3):2031-2041. PubMed ID: 34424427
[TBL] [Abstract][Full Text] [Related]
32. Immune Checkpoint Inhibitor-Induced Diabetes Mellitus: Potential Role of T Cells in the Underlying Mechanism.
Mourad D; Azar NS; Eid AA; Azar ST
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33672515
[TBL] [Abstract][Full Text] [Related]
33. An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors.
Esposito R; Fedele T; Orefice S; Cuomo V; Prastaro M; Canonico ME; Ilardi F; De Stefano F; Fiorillo L; Santoro C; Esposito G
Biomolecules; 2021 May; 11(6):. PubMed ID: 34067474
[TBL] [Abstract][Full Text] [Related]
34. Immune-related adverse events of checkpoint inhibitors: Insights into immunological dysregulation.
Yang H; Yao Z; Zhou X; Zhang W; Zhang X; Zhang F
Clin Immunol; 2020 Apr; 213():108377. PubMed ID: 32135278
[TBL] [Abstract][Full Text] [Related]
35. Current challenges of hematologic complications due to immune checkpoint blockade: a comprehensive review.
Ghanem P; Marrone K; Shanbhag S; Brahmer JR; Naik RP
Ann Hematol; 2022 Jan; 101(1):1-10. PubMed ID: 34962580
[TBL] [Abstract][Full Text] [Related]
36. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
Reynolds KL; Guidon AC
Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
[TBL] [Abstract][Full Text] [Related]
37. Clinical diagnosis and treatment of immune checkpoint inhibitor-associated adverse events in the digestive system.
Li Y; Kang X; Wang H; Guo X; Zhou J; Duan L; Si X; Zhang L; Liu X; Qian J; Zhang L
Thorac Cancer; 2020 Apr; 11(4):829-834. PubMed ID: 32107847
[TBL] [Abstract][Full Text] [Related]
38. Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer.
Kobayashi Y; Lim SO; Yamaguchi H
Semin Cancer Biol; 2020 Oct; 65():51-64. PubMed ID: 31874279
[TBL] [Abstract][Full Text] [Related]
39. The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors.
Karimian Z; Mavoungou S; Salem JE; Tubach F; Dechartres A
BMC Cancer; 2020 Nov; 20(1):1128. PubMed ID: 33225901
[TBL] [Abstract][Full Text] [Related]
40. Biomarkers related to immune checkpoint inhibitors therapy.
Li N; Hou X; Huang S; Tai R; Lei L; Li S; Abuliz A; Wang G; Yang S
Biomed Pharmacother; 2022 Mar; 147():112470. PubMed ID: 35074251
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
